MSI-H CRC
Oncology · 2025–2025
1decision
1medicine
1carried consumer input
8individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab; ipilimumab First-line treatment of microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC). | Jul 2025 | Not recommended | 8 individuals Rare Cancers Australia · Bowel Cancer Australia · Medical Oncology Group Australia |
Who spoke
Rare Cancers Australia · Bowel Cancer Australia · Medical Oncology Group Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.